All In Biotech

Free tool

FAERS Monitor: Harvoni

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 205834 or its brand name (Harvoni, Ledipasvir, Sofosbuvir). Reports on generic versions are filed under their own applications.

Reports

19,121

Serious

7,455

39% of reports

Hospitalization

2,708

Death reported

780

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue4,131
  • headache3,707
  • nausea1,242
  • drug ineffective1,140
  • diarrhoea913
  • hepatitis c887
  • insomnia835
  • vomiting442
  • dizziness440
  • drug dose omission436
  • hepatocellular carcinoma402
  • treatment failure374
  • rash362
  • asthenia338
  • arthralgia330

Reports by year received

View as table
YearReports
20101
20131
2014125
20154,134
20165,147
20174,537
20182,885
20191,344
2020414
2021221
2022160
202368
202434
202524
202626

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,035,038 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatitis cSignal88787.181.569,946
hepatocellular carcinomaSignal40261.355.522,551
headacheSignal3,7076.56.317,807
fatigueSignal4,1315.95.717,204
treatment failureSignal3745.04.51,186
insomniaSignal8353.53.21,469
drug dose omissionSignal4362.92.6546
nausea1,2421.71.6394
diarrhoea9131.61.5187
vomiting4421.00.90
asthenia3381.00.90
dizziness4401.00.90
drug ineffective1,1401.00.93
rash3620.90.83
arthralgia3300.90.86

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.